This test is most useful if any of these apply to you.
Fusobacterium is more common in stool from people with colorectal cancer in many studies. But this result covers a whole group of bacteria, while much of the cancer research measures one species, Fusobacterium nucleatum. A group-level result cannot identify that species or the particular strains most closely associated with tumors.
This is an exploratory marker. Its association with colorectal cancer is well supported, but using this stool result to guide screening, treatment, or surveillance has not been shown to improve health outcomes. There are no standardized clinical cutpoints or established targets for lowering it.
These bacteria grow in environments with little or no oxygen. Several species commonly live in dental plaque, and oral bacteria are swallowed with saliva. Some members of the group also occur in the digestive tract. Finding their DNA in stool does not establish that they recently moved from your mouth or that they have damaged your colon.
F. nucleatum is the species most extensively studied in colorectal cancer. Even within that species, different lineages behave differently. A lineage called F. nucleatum subspecies animalis C2 is particularly enriched in colorectal tumors and stool from people with colorectal cancer. Research that identifies this lineage provides more specific information than a result for the whole Fusobacterium group.
Laboratory experiments show that F. nucleatum can attach to human cells through surface proteins including FadA and Fap2. These proteins can also affect cell growth and immune responses. Human tumor studies have found associations between Fusobacterium and reduced infiltration by some cancer-fighting immune cells, although the immune pattern varies across tumors. A stool result does not measure these processes.
This test uses quantitative PCR to estimate the amount of Fusobacterium DNA in stool. PCR copies selected DNA sequences so they can be detected and quantified. The result reflects DNA in the collected sample, including DNA that may come from bacteria that are no longer alive.
Stool and colon tissue capture different bacterial populations. DNA passing through the intestine is different from bacteria attached to, or living within, a tumor. Findings from tumor biopsies therefore provide biological context but cannot be used to assign the same prognosis to your stool result.
Most of the strongest evidence compares people who already have colorectal cancer with people who don't. A meta-analysis of 12 studies found about eightfold higher odds of detecting F. nucleatum in samples from people with cancer. It combined stool and colon-tissue studies using several detection methods, and the pooled comparisons were unadjusted. This describes an association with existing cancer, not an eightfold increase in your future cancer risk.
The figures below concern research assays for F. nucleatum specifically. They are not validated performance estimates for this broader Fusobacterium result.
| Who Was Studied | What Was Compared | What They Found |
|---|---|---|
| 1,450 people with colorectal cancer and 1,421 controls across 10 studies | Stool F. nucleatum assays | Detected about 71 of every 100 cancers and correctly classified about 76 of every 100 controls |
| People with colorectal adenomas in the same meta-analysis | Stool F. nucleatum assays | Detected about 36 of every 100 people with adenomas |
| A development cohort of 309 people, followed by an independent validation cohort of 181 | FIT alone versus a model combining FIT with stool F. nucleatum | In the development cohort, cancer detection rose from 73.1% to 92.3%; correct classification of controls fell from 98.0% to 93.0% |
Researchers have also compared F. nucleatum with other bacteria. In a study involving 903 people, its stool ratio to Bifidobacterium detected 84.6% of colorectal cancers and correctly classified 92.3% of controls. That result belongs to the study's species-specific measurements and analysis. Dividing numbers from separate commercial tests does not recreate the validated research model.
These findings support continued development of bacterial markers alongside established screening. They also show their limits: cancers can have little detectable F. nucleatum, and many adenomas are missed. Detection in people without cancer means a positive result cannot diagnose cancer either.
In 105 people already diagnosed with colorectal cancer, higher preoperative stool F. nucleatum was associated with about threefold higher odds of a rectal versus colon tumor. Other studies, especially those examining tumor tissue, have reported different patterns by tumor location. Your stool result cannot locate a tumor.
A 740-person study examined Fusobacterium in surgically removed tumors and found an association with earlier recurrence. Its exploratory stool analysis included only 34 people and measured F. nucleatum specifically. Two of the four people with detectable stool DNA subsequently relapsed, compared with none of the 30 with undetectable DNA. Detection preceded those recurrences by up to three years, but so few events cannot establish a reliable surveillance test.
A separate study followed people after adenoma removal. Among 367 people in its retrospective cohort, higher pre-removal stool F. nucleatum was associated with about sixfold higher odds of another adenoma at follow-up colonoscopy. The researchers then evaluated prediction in a separate prospective cohort of 238 people. This promising finding has not established how a genus-level stool result should change your follow-up schedule.
Most survival evidence comes from tumor tissue. In 1,069 people from two U.S. cohorts, those whose tumors contained high F. nucleatum levels had about a 58% higher rate of death from colorectal cancer than those with undetectable tumor levels, after adjustment for several clinical and tumor characteristics. That association cannot be transferred to a stool measurement.
The association is more consistent for cancer than for adenomas. A study using stool sequencing in 500 screening participants found Fusobacterium enrichment in cancer but no association with adenomas. Other studies have found associations with adenomas, including research using colon-lining biopsies and the study of new adenomas after removal.
One often-cited study examined stool from primary care patients and a separate group of 150 people with colon biopsies and about a decade of follow-up. Bacterial detection in that biopsy cohort did not predict progression of colorectal growths. It was not a decade-long study of repeated stool testing.
Mouse experiments show that some F. nucleatum strains can promote intestinal tumor growth. Human studies establish a strong association but have not settled when the bacteria arrive or how much they contribute to cancer development. Tumors may create conditions that favor bacterial growth, while the bacteria may also influence tumor biology. The uneven findings in adenomas do not resolve that question.
F. nucleatum has also been associated with Crohn's disease. A study of 346 people found higher stool levels in the Crohn's group and investigated a combination with Faecalibacterium prausnitzii as a diagnostic marker. These were species-specific research measurements, and the combination has not established a diagnostic role for this genus-wide result.
Sequencing studies have linked F. nucleatum detection with changes in the surrounding bacterial community, including lower bacterial diversity in some analyses. Diversity describes how many different kinds of bacteria are present and how evenly they are represented. These associations do not make a single Fusobacterium result a validated measure of gut health or a diagnosis of microbial imbalance.
In dental plaque, F. nucleatum can bind other bacterial species and help them form mixed communities. Periodontitis damages the tissues that support your teeth. Studies have found differences in both oral and stool bacteria in people with this disease, providing a plausible connection between oral health and the gut.
That connection does not let a stool test diagnose gum disease or trace the bacteria to a particular tooth or gum pocket. The mouth and stool are different sampling sites, and even oral and stool measurements taken from the same person may behave differently.
In 3,459 Swiss adults followed for 12 years, blood antibodies to F. nucleatum were associated with about a 63% higher rate of coronary heart disease after adjustment for several risk factors. Antibodies reflect an immune response to exposure. They are a different measurement from bacterial DNA in stool, so this finding does not establish a cardiovascular-risk interpretation for your stool result.
Repeated samples can help researchers distinguish persistent detection from a temporary finding. For personal care, there is no validated amount of change that signals improvement or worsening, and no evidence-based target to pursue. A falling result has not been shown to mean that your colorectal cancer risk has fallen.
Evidence-backed interventions that affect your Fusobacterium level
Fusobacterium is best interpreted alongside these tests.
Fusobacterium is included in these pre-built panels.
See what your gut microbes are actually doing, not just whether your digestion feels off, and track the balance over time.